- •Preface to the First Edition
- •Preface to the Second Edition
- •Contents
- •Diagnostic Challenges
- •Expert Centers
- •Patient Organizations
- •Clinical Trials
- •Research in Orphan Lung Diseases
- •Orphan Drugs
- •Orphanet
- •Empowerment of Patients
- •Conclusions
- •References
- •Introduction
- •Challenges to Overcome in Order to Undertake Quality Clinical Research
- •Lack of Reliable Data on Prevalence
- •Small Number of Patients
- •Identifying Causation/Disease Pathogenesis
- •Disease Complexity
- •Lack of Access to a Correct Diagnosis
- •Delay in Diagnosis
- •Challenges But Not Negativity
- •Some Success Stories
- •The Means to Overcome the Challenges of Clinical Research: Get Bigger Numbers of Well-Characterized Patients
- •The Importance of Patient Organizations
- •National and International Networks
- •End Points for Trials: Getting Them Right When Numbers Are Small and Change Is Modest
- •Orphan Drug Development
- •Importance of Referral Centers
- •Looking at the Future
- •The Arguments for Progress
- •Concluding Remarks
- •References
- •3: Chronic Bronchiolitis in Adults
- •Introduction
- •Cellular Bronchiolitis
- •Follicular Bronchiolitis
- •Respiratory Bronchiolitis
- •Airway-Centered Interstitial Fibrosis
- •Proliferative Bronchiolitis
- •Diagnosis
- •Chest Imaging Studies
- •Pulmonary Function Testing
- •Lung Biopsy
- •Mineral Dusts
- •Organic Dusts
- •Volatile Flavoring Agents
- •Infectious Causes of Bronchiolitis
- •Idiopathic Forms of Bronchiolitis
- •Connective Tissue Diseases
- •Organ Transplantation
- •Hematopoietic Stem Cell Transplantation
- •Drug-Induced Bronchiolitis
- •Treatment
- •Constrictive Bronchiolitis
- •Follicular Bronchiolitis
- •Airway-Centered Interstitial Fibrosis
- •Proliferative Bronchiolitis
- •References
- •Background and Epidemiology
- •Pathophysiology
- •Host Characteristics
- •Clinical Manifestations
- •Symptoms
- •Laboratory Evaluation
- •Skin Testing
- •Serum Precipitins
- •Eosinophil Count
- •Total Serum Immunoglobulin E Levels
- •Recombinant Antigens
- •Radiographic Imaging
- •Pulmonary Function Testing
- •Histology
- •Diagnostic Criteria
- •Historical Diagnostic Criteria
- •Rosenberg and Patterson Diagnostic Criteria
- •ISHAM Diagnostic Criteria
- •Cystic Fibrosis Foundation Diagnostic Criteria
- •General Diagnostic Recommendations
- •Allergic Aspergillus Sinusitis (AAS)
- •Natural History
- •Treatment
- •Corticosteroids
- •Antifungal Therapy
- •Monoclonal Antibodies
- •Monitoring for Treatment Response
- •Conclusions
- •References
- •5: Orphan Tracheopathies
- •Introduction
- •Anatomical Considerations
- •Clinical Presentation
- •Etiological Considerations
- •Idiopathic Subglottic Stenosis
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Introduction and Clinical Presentation
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheomalacia
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheobronchomegaly
- •Introduction
- •Clinical Features
- •Pathophysiology
- •Pulmonary Function Studies
- •Imaging Studies
- •Treatment
- •Tracheopathies Associated with Systemic Diseases
- •Relapsing Polychondritis
- •Introduction
- •Clinical Features
- •Laboratory Findings
- •Pulmonary Function and Imaging Studies
- •Treatment
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheobronchial Amyloidosis
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Sarcoidosis
- •Introduction
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Orphan Tracheopathies: Conclusions
- •References
- •6: Amyloidosis and the Lungs and Airways
- •Introduction
- •Diagnosis and Evaluation of Amyloidosis
- •Systemic AA Amyloidosis
- •Systemic AL Amyloidosis
- •Amyloidosis Localised to the Respiratory Tract
- •Laryngeal Amyloidosis
- •Tracheobronchial Amyloidosis
- •Parenchymal Pulmonary Amyloidosis
- •Pulmonary Amyloidosis Associated with Sjögren’s Disease
- •Conclusions
- •References
- •Introduction
- •Pathophysiology
- •Genetic Predisposition
- •Immune Dysregulation
- •Epidemiology
- •Incidence and Prevalence
- •Triggering Factors
- •Clinical Manifestations
- •General Symptoms
- •Pulmonary Manifestations
- •Ear, Nose, and Throat (ENT) Manifestations
- •Neurological Manifestations
- •Skin Manifestations
- •Cardiac Manifestations
- •Gastrointestinal Involvement
- •Renal Manifestations
- •Ophthalmological Manifestations
- •Complementary Investigations
- •Diagnosis
- •Diagnostic Criteria
- •Prognosis and Outcomes
- •Phenotypes According to the ANCA Status
- •Treatment
- •Therapeutic Strategies
- •Remission Induction
- •Maintenance Therapy
- •Other Treatments
- •Prevention of AEs
- •Conclusions
- •References
- •8: Granulomatosis with Polyangiitis
- •A Brief Historical Overview
- •Epidemiology
- •Pathogenesis
- •Clinical Manifestations
- •Constitutional Symptoms
- •Ear, Nose, and Throat (ENT) Manifestations
- •Pulmonary Manifestations
- •Kidney and Urological Manifestations
- •Kidney Manifestations
- •Urological Manifestations
- •Neurological Manifestations
- •Peripheral Nervous System (PNS) Manifestations
- •Central Nervous System (CNS) Manifestations
- •Spinal Cord and Cranial Nerve Involvement
- •Skin and Oral Mucosal Manifestations
- •Eye Manifestations
- •Cardiac Involvement
- •Gastrointestinal Manifestations
- •Gynecological and Obstetric Manifestations
- •Venous Thrombosis and Other Vascular Events
- •Other Manifestations
- •Pediatric GPA
- •Diagnosis
- •Diagnostic Approach
- •Laboratory Investigations
- •Biology
- •Immunology
- •Pathology
- •Treatment
- •Glucocorticoids
- •Cyclophosphamide
- •Rituximab
- •Other Current Induction Approaches
- •Other Treatments in GPA
- •Intravenous Immunoglobulins
- •Plasma Exchange
- •CTLA4-Ig (Abatacept)
- •Cotrimoxazole
- •Other Agents
- •Principles of Treatment for Relapsing and Refractory GPA
- •Outcomes and Prognostic Factors
- •Survival and Causes of Deaths
- •Relapse
- •Damage and Disease Burden on Quality of Life
- •Conclusions
- •References
- •9: Alveolar Hemorrhage
- •Introduction
- •Clinical Presentation
- •Diagnosis (Table 9.1, Fig. 9.3)
- •Pulmonary Capillaritis
- •Histology (Fig. 9.4)
- •Etiologies
- •ANCA-Associated Small Vessel Vasculitis: Granulomatosis with Polyangiitis (GPA)
- •ANCA-Associated Small Vessel Vasculitis: Microscopic Polyangiitis
- •Isolated Pulmonary Capillaritis
- •Systemic Lupus Erythematosus
- •Antiphospholipid Antibody Syndrome
- •Anti-Basement Membrane Antibody Disease (Goodpasture Syndrome)
- •Lung Allograft Rejection
- •Others
- •Bland Pulmonary Hemorrhage (Fig. 9.5)
- •Histology
- •Etiologies
- •Idiopathic Pulmonary Hemosiderosis
- •Drugs and Medications
- •Coagulopathy
- •Valvular Heart Disease and Left Ventricular Dysfunction
- •Other
- •Histology
- •Etiologies
- •Hematopoietic Stem Cell Transplantation (HSCT)
- •Cocaine Inhalation
- •Acute Exacerbation of Interstitial Lung Disease
- •Acute Interstitial Pneumonia
- •Acute Respiratory Distress Syndrome
- •Miscellaneous Causes
- •Etiologies
- •Pulmonary Capillary Hemangiomatosis
- •Treatment
- •Conclusions
- •References
- •Takayasu Arteritis
- •Epidemiology
- •Pathologic Features
- •Pathogenesis
- •Clinical Features
- •Laboratory Findings
- •Imaging Studies
- •Therapeutic Management
- •Prognosis
- •Behçet’s Disease
- •Epidemiology
- •Pathologic Features
- •Pathogenesis
- •Diagnostic Criteria
- •Clinical Features
- •Pulmonary Artery Aneurysm
- •Pulmonary Artery Thrombosis
- •Pulmonary Parenchymal Involvement
- •Laboratory Findings
- •Imaging Studies
- •Therapeutic Management
- •Treatment of PAA
- •Treatment of PAT
- •Prognosis
- •References
- •Introduction
- •Portopulmonary Hypertension (PoPH)
- •Epidemiology and Risk Factors
- •Molecular Pathogenesis
- •PoPH Treatment
- •Hepatopulmonary Syndrome (HPS)
- •Epidemiology and Risk Factors
- •Molecular Pathogenesis
- •HPS Treatment
- •Conclusion
- •References
- •12: Systemic Sclerosis and the Lung
- •Introduction
- •Risk factors for SSc-ILD
- •Genetic Associations
- •Clinical Presentation of SSc-ILD
- •Pulmonary Function Tests (PFTs)
- •Imaging
- •Management
- •References
- •13: Rheumatoid Arthritis and the Lungs
- •Introduction
- •Epidemiology
- •Risk Factors for ILD (Table 13.3)
- •Pathogenesis
- •Clinical Features and Diagnosis
- •Treatments
- •Prognosis
- •Epidemiology
- •Risk Factors
- •Clinical Features, Diagnosis, and Outcome
- •Subtypes or RA-AD
- •Obliterative Bronchiolitis
- •Bronchiectasis
- •COPD
- •Cricoarytenoid Involvement
- •Pleural Disease
- •Conclusion
- •References
- •Introduction
- •Systemic Lupus Erythematosus
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Pleural Disease
- •Shrinking Lung Syndrome
- •Thrombotic Manifestations
- •Interstitial Lung Disease
- •Other Pulmonary Manifestations
- •Prognosis
- •Sjögren’s Syndrome
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Airway Disorders
- •Lymphoproliferative Disease
- •Interstitial Lung Disease
- •Prognosis
- •Mixed Connective Tissue Disease
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Pulmonary Hypertension
- •Interstitial Lung Disease
- •Prognosis
- •Myositis
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations and Treatments
- •Interstitial Lung Disease
- •Respiratory Muscle Weakness
- •Other Pulmonary Manifestations
- •Prognosis
- •Other Therapeutic Options in CTD-ILD
- •Lung Transplantation
- •Conclusion
- •References
- •Introduction
- •Diagnostic Criteria
- •Controversies in the Diagnostic Criteria
- •Typical Clinical Features
- •Disease Progression and Prognosis
- •Summary
- •References
- •Introduction
- •Histiocytes and Dendritic Cells
- •Introduction
- •Cellular and Molecular Pathogenesis
- •Pathology
- •Clinical Presentation
- •Treatment and Prognosis
- •Erdheim-Chester Disease
- •Epidemiology
- •Cellular and Molecular Pathogenesis
- •Histopathology and Immunohistochemistry
- •Clinical Presentation
- •Investigation/Diagnosis
- •Chest Studies
- •Cardiovascular Imaging
- •CNS Imaging
- •Bone Radiography
- •Other Imaging Findings and Considerations
- •Disease Monitoring
- •Pathology
- •Management/Treatment
- •Prognosis
- •Rosai-Dorfman Destombes Disease
- •Epidemiology
- •Etiology/Pathophysiology
- •Histopathology and Immunohistochemistry
- •Clinical Presentation
- •Investigation/Diagnosis
- •Management/Treatment
- •Prognosis
- •Conclusions
- •Diagnostic Criteria for Primary Histiocytic Disorders of the Lung
- •References
- •17: Eosinophilic Pneumonia
- •Introduction
- •Eosinophil Biology
- •Physiologic and Immunologic Role of Eosinophils
- •Release of Mediators
- •Targeting the Eosinophil Cell Lineage
- •Historical Perspective
- •Clinical Presentation
- •Pathology
- •Diagnosis
- •Eosinophilic Lung Disease of Undetermined Cause
- •Idiopathic Chronic Eosinophilic Pneumonia
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Bronchoalveolar Lavage
- •Lung Function Tests
- •Treatment
- •Outcome and Perspectives
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Bronchoalveolar Lavage
- •Lung Function Tests
- •Lung Biopsy
- •Treatment and Prognosis
- •Eosinophilic Granulomatosis with Polyangiitis
- •History and Nomenclature
- •Pathology
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Pathogenesis
- •Diagnosis
- •Treatment and Prognosis
- •Long-Term Outcome
- •Hypereosinophilic Syndrome
- •Pathogenesis
- •Clinical and Imaging Features
- •Laboratory Studies
- •Treatment and Prognosis
- •Eosinophilic Pneumonias of Parasitic Origin
- •Tropical Eosinophilia [191]
- •Ascaris Pneumonia
- •Eosinophilic Pneumonia in Larva Migrans Syndrome
- •Strongyloides Stercoralis Infection
- •Eosinophilic Pneumonias in Other Infections
- •Allergic Bronchopulmonary Aspergillosis
- •Pathogenesis
- •Diagnostic Criteria
- •Biology
- •Imaging
- •Treatment
- •Bronchocentric Granulomatosis
- •Miscellaneous Lung Diseases with Associated Eosinophilia
- •References
- •Introduction
- •Pulmonary Langerhans’ Cell Histiocytosis
- •Epidemiology
- •Pathogenesis
- •Diagnosis
- •Clinical Features
- •Extrathoracic Lesions
- •Pulmonary Function Tests
- •Chest Radiography
- •High-Resolution Computed Tomography (HRCT)
- •Bronchoscopy and Bronchoalveolar Lavage (BAL)
- •Lung Biopsy
- •Pathology
- •Treatment
- •Course and Prognosis
- •Case Report I
- •Introduction
- •Epidemiology
- •Clinical Features
- •Histopathological Findings
- •Radiologic Findings
- •Prognosis and Therapy
- •Desquamative Interstitial Pneumonia
- •Epidemiologic and Clinical Features
- •Histopathological Findings
- •Radiological Findings
- •Prognosis and Therapy
- •Conclusion
- •References
- •19: Lymphangioleiomyomatosis
- •Introduction
- •Pathogenesis
- •Presentation
- •Prognosis
- •Management
- •General Measures
- •Parenchymal Lung Disease
- •Pleural Disease
- •Renal Angiomyolipoma
- •Abdominopelvic Lymphatic Disease
- •Pregnancy
- •Tuberous Sclerosis
- •Drug Treatment
- •Bronchodilators
- •mTOR Inhibitors
- •Anti-Oestrogen Therapy
- •Experimental Therapies
- •Interventions for Advanced Disease
- •Oxygen Therapy
- •Pulmonary Hypertension
- •References
- •20: Diffuse Cystic Lung Disease
- •Introduction
- •Lymphangioleiomyomatosis
- •Pathogenesis
- •Pathologic and Radiographic Characteristics
- •Diagnostic Approach
- •Pulmonary Langerhans Cell Histiocytosis (PLCH)
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Birt-Hogg-Dubé Syndrome (BHD)
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Lymphoproliferative Disorders
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Amyloidosis
- •Light Chain Deposition Disease (LCDD)
- •Conclusion
- •References
- •Introduction
- •Lymphatic Development
- •Clinical Presentation of Lymphatic Disorders
- •Approaches to Diagnosis and Management of Congenital Lymphatic Anomalies
- •Generalized Lymphatic Anomaly
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Course/Prognosis
- •Management
- •Kaposiform Lymphangiomatosis
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Gorham Stout Disease
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Channel-Type LM/Central Conducting LM
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Yellow Nail Syndrome
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Summary
- •References
- •Introduction
- •Historical Note
- •Epidemiology
- •Pathogenesis
- •Surfactant Homeostasis in PAP
- •GM-CSF Signaling Disruption
- •Myeloid Cell Dysfunction
- •GM-CSF Autoantibodies
- •Lymphocytosis
- •Clinical Manifestations
- •Clinical Presentation
- •Secondary Infections
- •Pulmonary Fibrosis
- •Diagnosis
- •Pulmonary Function Testing
- •Radiographic Assessment
- •Bronchoscopy and Bronchoalveolar Lavage
- •Laboratory Studies and Biomarkers
- •GM-CSF Autoantibodies
- •Genetic Testing
- •Lung Pathology
- •Diagnostic Approach to the Patient with PAP
- •Natural History and Prognosis
- •Treatment
- •Whole-Lung Lavage
- •Subcutaneous GM-CSF
- •Inhaled GM-CSF
- •Other Approaches
- •Conclusions and Future Directions
- •References
- •Introduction
- •Epidemiology
- •Gastric Contents
- •Pathobiology of GER/Microaspirate in the Lungs of Patients with IPF
- •GER and the Microbiome
- •Diagnosis
- •Clinical History/Physical Exam
- •Investigations
- •Esophageal Physiology
- •Upper Esophageal Sphincter
- •Esophagus and Peristalsis
- •Lower Esophageal Sphincter and Diaphragm
- •Esophageal pH and Impedance Testing
- •High Resolution Esophageal Manometry
- •Esophagram/Barium Swallow
- •Bronchoalveolar Lavage/Sputum: Biomarkers
- •Treatment
- •Anti-Acid Therapy (PPI/H2 Blocker)
- •GER and Acute Exacerbations of IPF
- •Suggested Approach
- •Summary and Future Directions
- •References
- •Introduction
- •Familial Interstitial Pneumonia
- •Telomere Related Genes
- •Genetic
- •Telomere Length
- •Pulmonary Involvement
- •Interstitial Lung Disease
- •Other Lung Disease
- •Hepatopulmonary Syndrome
- •Emphysema
- •Extrapulmonary Manifestations
- •Mucocutaneous Involvement
- •Hematological Involvement
- •Liver Involvement
- •Other Manifestations
- •Treatment
- •Telomerase Complex Agonists
- •Lung Transplantation
- •Surfactant Pathway
- •Surfactant Protein Genes
- •Pulmonary Involvement
- •Treatment
- •Heritable Forms of Pulmonary Fibrosis with Autoimmune Features
- •TMEM173
- •COPA
- •Pulmonary Alveolar Proteinosis
- •GMCSF Receptor Mutations
- •GATA2
- •MARS
- •Lysinuric Protein Intolerance
- •Lysosomal Diseases
- •Hermansky-Pudlak Syndrome
- •Lysosomal Storage Disorders
- •FAM111B, NDUFAF6, PEPD
- •Conclusion
- •References
- •Introduction
- •Pathophysiology
- •Clinical Presentation
- •Epidemiology
- •Genetic Causes of Bronchiectasis
- •Disorders of Mucociliary Clearance
- •Cystic Fibrosis
- •Primary Ciliary Dyskinesia
- •Other Ciliopathies
- •X-Linked Agammaglobulinemia
- •Chronic Granulomatous Disease and Other Disorders of Neutrophil Function
- •Other Genetic Disorders Predisposing to Bronchiectasis
- •Idiopathic Bronchiectasis
- •Diagnosis of Bronchiectasis
- •Management of Patients with Bronchiectasis
- •Airway Clearance Therapy (ACT)
- •Management of Infections
- •Immune Therapy
- •Surgery
- •Novel Therapies for Managing Cystic Fibrosis
- •Summary
- •References
- •Pulmonary Arteriovenous Malformations
- •Background Pulmonary AVMs
- •Anatomy Pulmonary AVMs
- •Clinical Presentation of Pulmonary AVMs
- •Screening Pulmonary AVMs
- •Treatment Pulmonary AVMs
- •Children with Hereditary Hemorrhagic Telangiectasia
- •Pulmonary Hypertension
- •Pulmonary Hypertension Secondary to Liver Vascular Malformations
- •Pulmonary Arterial Hypertension
- •Background HHT
- •Pathogenesis
- •References
- •27: Pulmonary Alveolar Microlithiasis
- •Introduction
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Diagnosis
- •Management
- •Summary
- •References
- •Introduction
- •Hermansky-Pudlak Syndrome
- •Telomerase-Associated Pulmonary Fibrosis
- •Lysosomal Storage Diseases
- •Lysinuric Protein Intolerance
- •Familial Hypocalciuric Hypercalcemia
- •Surfactant Dysfunction Disorders
- •Concluding Remarks
- •References
- •Introduction
- •Background
- •Image Acquisition
- •Key Features of Fibrosis
- •Ancillary Features of Fibrosis
- •Other Imaging Findings in FLD
- •Probable UIP-IPF
- •Indeterminate
- •Alternative Diagnosis
- •UIP in Other Fibrosing Lung Diseases
- •Pleuroparenchymal Fibroelastosis (PPFE)
- •Combined Pulmonary Fibrosis and Emphysema
- •Chronic Hypersensitivity Pneumonitis
- •Other Fibrosing Lung Diseases
- •Fibrosing Sarcoidosis
- •CTD-ILD and Drug-Induced FLD
- •Complications
- •Prognosis
- •Computer Analysis of CT Imaging
- •The Progressive Fibrotic Phenotype
- •Other Imaging Techniques
- •Conclusion
- •References
- •Introduction
- •Bronchoalveolar Lavage (BAL)
- •Technique
- •Interpretation
- •Transbronchial Biopsy (TBB)
- •Transbronchial Lung Cryobiopsy (TLCB)
- •References
- •Introduction
- •Overview of ILD Diagnosis
- •Clinical Assessment
- •Radiological Assessment
- •Laboratory Assessment
- •Integration of Individual Features
- •Multidisciplinary Discussion
- •Diagnostic Ontology
- •Conclusions
- •References
- •Introduction
- •Idiopathic Pulmonary Fibrosis
- •Chronic Hypersensitivity Pneumonitis
- •Connective Tissue Disease
- •Drug-Induced Lung Diseases
- •Radiation Pneumonitis
- •Asbestosis
- •Hermansky-Pudlak Syndrome
- •Risk Factors for Progression
- •Diagnosis
- •Pharmacological Management
- •Conclusions
- •References
- •Historical Perspective
- •Epidemiology and Etiologies
- •Tobacco Smoking and Male Sex
- •Genetic Predisposition
- •Systemic Diseases
- •Other Etiological Contexts
- •Clinical Manifestations
- •Pulmonary Function and Physiology
- •Imaging
- •Computed Tomography Characteristics and Patterns
- •Thick-Walled Large Cysts
- •Imaging Phenotypes
- •Pitfalls
- •Pathology
- •Diagnosis
- •CPFE Is a Syndrome
- •Biology
- •Complications and Outcome
- •Mortality
- •Pulmonary Hypertension
- •Lung Cancer
- •Acute Exacerbation of Pulmonary Fibrosis
- •Other Comorbidities and Complications
- •Management
- •General Measures and Treatment of Emphysema
- •Treatment of Pulmonary Fibrosis
- •Management of Pulmonary Hypertension
- •References
- •Acute Interstitial Pneumonia (AIP)
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Desquamative Interstitial Pneumonia (DIP)
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •References
- •Organizing Pneumonias
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Imaging
- •Multifocal Form
- •Isolated Nodular Form
- •Other Imaging Patterns
- •Histopathological Diagnosis of OP Pattern
- •Etiological Diagnosis of OP
- •Treatment
- •Clinical Course and Outcome
- •Severe Forms of OP with Respiratory Failure
- •Acute Fibrinous and Organizing Pneumonia
- •Granulomatous Organizing Pneumonia
- •Acute Interstitial Pneumonia
- •Epidemiology
- •Clinical Picture
- •Imaging
- •Histopathology
- •Diagnosis
- •Treatment
- •Outcome
- •References
- •36: Pleuroparenchymal Fibroelastosis
- •Introduction
- •Epidemiology
- •Clinical Manifestations
- •Laboratory Findings
- •Respiratory Function
- •Radiologic Features
- •Pathologic Features
- •Diagnosis
- •Treatment
- •Prognosis
- •Conclusions
- •References
- •Introduction
- •Acute Berylliosis
- •Chronic Beryllium Disease
- •Exposure
- •Epidemiology
- •Immunopathogenesis and Pathology
- •Genetics
- •Clinical Description and Natural History
- •Treatment and Monitoring
- •Indium–Tin Oxide-Lung Disease
- •Hard Metal Lung
- •Flock Worker’s Disease
- •Asbestosis
- •Nanoparticle Induced ILD
- •Flavoring-Induced Lung Disease
- •Silica-Induced Interstitial Lung Disease
- •Chronic Silicosis
- •Acute and Accelerated Silicosis
- •Chronic Obstructive Disease in CMDLD
- •Simple CMDLD
- •Complicated CMDLD
- •Conclusion
- •References
- •38: Unclassifiable Interstitial Lung Disease
- •Introduction
- •Diagnostic Scenarios
- •Epidemiology
- •Clinical Presentation
- •Diagnosis
- •Clinical Features
- •Radiology
- •Laboratory Investigations
- •Pathology
- •Conclusion
- •References
- •39: Lymphoproliferative Lung Disorders
- •Introduction
- •Nodular Lymphoid Hyperplasia
- •Lymphocytic Interstitial Pneumonia (LIP)
- •Follicular Bronchitis/Bronchiolitis
- •Castleman Disease
- •Primary Pulmonary Lymphomas
- •Primary Pulmonary MALT B Cell Lymphoma
- •Pulmonary Plasmacytoma
- •Follicular Lymphoma
- •Lymphomatoid Granulomatosis
- •Primary Pulmonary Hodgkin Lymphoma (PPHL)
- •Treatment
- •References
- •Introduction
- •Late-Onset Pulmonary Complications
- •Bronchiolitis Obliterans (BO)
- •Pathophysiology
- •Diagnosis
- •Management of BOS
- •Post-HSCT Organizing Pneumonia
- •Other Late-Onset NonInfectious Pulmonary Complications (LONIPCs)
- •Conclusion
- •References
- •Introduction
- •Pulmonary Hypertension Associated with Sarcoidosis (Group 5.2)
- •PH Associated with Pulmonary Langerhans Cell Histiocytosis (Group 5.2)
- •PH in Combined Pulmonary Fibrosis and Emphysema (Group 3.3)
- •PH Associated with Lymphangioleiomyomatosis (Group 3)
- •Hereditary Hemorrhagic Telangiectasia (Group 1.2)
- •Pulmonary Veno-Occlusive Disease (Group 1.5)
- •Small Patella Syndrome (Group 1.2)
- •Conclusion
- •References
- •Introduction
- •Epidemiology
- •Timing, Chronology, Delay Time
- •Route of Administration
- •Patterns of Involvement [3, 4]
- •Drugs and Agents Fallen Out of Favor
- •Drug-Induced Noncardiac Pulmonary Edema
- •Drug-Induced Cardiogenic Pulmonary Edema
- •The “Chemotherapy Lung”
- •Drug-Induced/Iatrogenic Alveolar Hemorrhage
- •Drugs
- •Superwarfarin Rodenticides
- •Transfusion Reactions: TACO–TRALI
- •Acute Eosinophilic Pneumonia
- •Acute Granulomatous Interstitial Lung Disease
- •Acute Organizing Pneumonia (OP), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), or Acute Fibrinous Organizing Pneumonia (AFOP) Patterns
- •Acute Amiodarone-Induced Pulmonary Toxicity (AIPT)
- •Accelerated Pulmonary Fibrosis
- •Acute Exacerbation of Previously Known (Idiopathic) Pulmonary Fibrosis
- •Anaphylaxis
- •Acute Vasculopathy
- •Drug-Induced/Iatrogenic Airway Emergencies
- •Airway Obstruction as a Manifestation of Anaphylaxis
- •Drug-Induced Angioedema
- •Hematoma Around the Upper Airway
- •The “Pill Aspiration Syndrome”
- •Catastrophic Drug-Induced Bronchospasm
- •Peri-operative Emergencies (Table 42.8)
- •Other Rare Presentations
- •Pulmonary Nodules and Masses
- •Pleuroparenchymal Fibroelastosis
- •Late Radiation-Induced Injury
- •Chest Pain
- •Rebound Phenomenon
- •Recall Pneumonitis
- •Thoracic Bezoars: Gossipybomas
- •Respiratory Diseases Considered Idiopathic That May Be Drug-Induced (Table 42.4)
- •Eye Catchers
- •Conclusion
- •References
- •Cancer Mimics of Organizing Pneumonia
- •Lung Adenocarcinoma/Bronchioloalveolar Carcinoma
- •Primary Pulmonary Lymphoma
- •Cancer Mimics of Interstitial Lung Diseases
- •Lymphangitic Carcinomatosis
- •Epithelioid Hemangio-Endothelioma
- •Lymphomatoid Granulomatosis
- •Cystic Tumors
- •Cavitating Tumors
- •Intrathoracic Pseudotumors
- •Respiratory Papillomatosis
- •Pulmonary Langerhans Cell Histiocytosis
- •References
- •Index
27 Pulmonary Alveolar Microlithiasis |
483 |
|
|
Patients who develop spontaneous pneumothorax may not respond to conservative treatment with chest tube placement [82] and may require early surgical pleurodesis.
Patients with end-stage disease—especially those with right heart failure or chronic hypoxemic respiratory failure— should be referred to regional lung transplant centers. Optimal timing is not clear given the insidious nature of PAM and the lack of prognostic biomarkers or models [4]. As of late 2019, UNOS had records of lung transplantation being performed in 20 PAM patients [83–89]. The most common approach was bilateral lung transplantation (15/20 patients), although single lung transplantation has also been performed. Pleural adhesions and calci cations may make resection of the native lung during transplantation more technically dif cult, but strategies exist to mitigate risk [87, 90]. Transplant outcomes for PAM patients have not been compared to outcomes of patients with other lung diseases, but available reports in the world literature are reassuring. Importantly, since the rst transplant for PAM almost 30 years ago, no recurrence of alveolar microlithiasis has been reported in the allografts, as would be expected based on our new understanding of disease pathogenesis [21].
Summary
PAM is a hereditary disease characterized by the deposition of calcium phosphate crystals in the alveoli of the lungs caused by mutations in the type IIb sodium phosphate co- transporter. Patients typically present in their second or third decade of life and are often asymptomatic or only mildly dyspneic at the time of diagnosis, even when the imaging suggests extensive lung involvement. Characteristic chest tomography with widespread microcalci cations, diffuse ground-glass opacities, and dense airspace consolidations is frequently diagnostic, especially in the setting of a positive family history. Progressive disease ultimately results in worsening exertional dyspnea and respiratory failure. Treatment is primarily supportive. In patients with end-stage disease, lung transplantation may be an option; and timely referral for evaluation is essential. Recent development of an animal model has led to promising avenues of inquiry for further trials.
Box 27.1 Clinical Vignette
A 24-year-old male graduate student presents to clinic for evaluation of abnormal chest imaging. He had recently injured his shoulder in a minor car accident, and X-ray incidentally noted a diffuse micronodular pattern that prompted computed tomography of the chest.
He is asymptomatic. He has no environmental or occupational exposures. He is unsure whether there is any family history of respiratory diseases. Physical examination and laboratory data are unremarkable. Patient grew up in a region with endemic tuberculosis, so consecutive acid-fast bacilli smears and cultures are obtained and return negative. Given characteristic imaging, he is diagnosed with pulmonary alveolar microlithiasis. Whole genome sequencing for SLC34A2 reveals a mutation consistent with the diagnosis.
The patient’s clinical status remains stable for decades until he develops insidious onset progressive dyspnea on exertion and requires supplemental oxygen. He is ultimately referred for bilateral lung transplant, which he undergoes successfully.
484 |
C. D. Lampl et al. |
|
|
Box 27.2 Diagnostic Criteria
De nite PAM
Characteristic HRCT ndings PLUS
Histopathologic evidence of PAM on expectorated sputum, bronchoalveolar lavage, transbronchial biopsies, or surgical lung biopsy
OR
SLC34A2 mutation OR
Affected rst degree relative
Likely PAM
Characteristic HRCT ndings
AND
No alternate diagnosis
Based on algorithm recently proposed by our group (Kosciuk P, Meyer C, Wikenheiser-Brokamp KA, McCormack FX Eur Respir Rev 2020). No validated criteria exist at present.
References
1.\Malpighi M. Manoscritti vol XII foglio 81. Marcello Malpighi e i suoi seritti sugli organii del respiro. Anzalone M, editor. Bologna; 1966.
2.\Harbitz F. Extensive calci cation of the lungs as a distinct disease. Arch Intern Med. 1918;XXI(1):139–46.
3.\Puhr L. Mikrolithiasis alveolaris pulmonum. Virchows Arch. 1933;290(1):156–60.
4.\Castellana G, |
et al. |
Pulmonary |
alveolar microlithiasis: review |
of the 1022 |
cases |
reported |
worldwide. Eur Respir Rev. |
2015;24(138):607–20.
5.\Ucan ES, et al. Pulmonary alveolar microlithiasis: review of Turkish reports. Thorax. 1993;48(2):171–3.
6.\Tiedjen KU, Kosberg R, Kruger G. Pulmonary microlithiasis following iodine lipiodol lymphography? Radiologe. 1986;26(10):460–3.
7.\Chang AR. Pulmonary alveolar microlithiasis. Pathology. 1980;12(2):164–7, 282–3.
8.\Sosman MC, et al. The familial occurrence of pulmonary alveolar microlithiasis. Am J Roentgenol Radium Therapy, Nucl Med. 1957;77(6):947–1012.
9.\Mariotta S, et al. Pulmonary alveolar microlithiasis: review of Italian reports. Eur J Epidemiol. 1997;13(5):587–90.
10.\Hagiwara K, Johkoh T, Tachibana T. Pulmonary alveolar microlithiasis. In: Trapnell BC, Panos RJ, McCormack F, editors. Molecular basis of lung disease, insight from rare lung disorders. New Jersey: Humana Press; 2009.
11.\Huqun, et al. Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. Am J Respir Crit Care Med. 2007;175(3):263–8.
12.\Moran CA, et al. Pulmonary alveolar microlithiasis. A clinicopathologic and chemical analysis of seven cases. Arch Pathol Lab Med. 1997;121(6):607–11.
13.\Portnoy LM, Amadeo B, Hennigar GR. Pulmonary alveolar microlithiasis. An unusual case (associated with Milk-alkali syndrome). Am J Clin Pathol. 1964;41:194–201.
14.\Siddiqui NA, Fuhrman CR. Best cases from the AFIP: pulmonary alveolar microlithiasis. Radiographics. 2011;31(2):585–90.
15.\Kawakami M, Sato S, Takishima T. Electron microscopic studies on pulmonary alveolar microlithiasis. Tohoku J Exp Med. 1978;126(4):343–61.
16.\Barnard NJ, et al. Pulmonary alveolar microlithiasis. A new analytical approach. Histopathology. 1987;11(6):639–45.
17.\Chalmers AG, Wyatt J, Robinson PJ. Computed tomographic and pathological ndings in pulmonary alveolar microlithiasis. Br J Radiol. 1986;59(700):408–11.
18.\Pracyk JB, et al. Composition of lung lavage in pulmonary alveolar microlithiasis. Respiration. 1996;63(4):254–60.
19.\Malhotra B, et al. Pulmonary alveolar microlithiasis with calci ed pleural plaques. Lung India. 2010;27(4):250–2.
20.\Pant K, et al. Pulmonary alveolar microlithiasis with pleural calci - cation and nephrolithiasis. Chest. 1990;98(1):245–6.
21.\Samano MN, et al. Lung transplantation for pulmonary alveolar microlithiasis: a case report. Clinics (Sao Paulo). 2010;65(2):233–6.
22.\Ghosh GC, et al. Pulmonary alveolar microlithiasis: a rare cause of right heart failure. BMJ Case Rep. 2013;2013:bcr2013010218.
23.\Terada T. Pulmonary alveolar microlithiasis with cor pulmonale: an autopsy case demonstrating a marked decrease in pulmonary vascular beds. Respir Med. 2009;103(11):1768–71.
24.\Corut A, et al. Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis. Am J Hum Genet. 2006;79(4):650–6.
25.\Zhang XD, et al. Pulmonary alveolar microlithiasis: a case report and review of the literature. Exp Ther Med. 2018;15(1):831–7.
26.\Izumi H, et al. A novel SLC34A2 mutation in a patient with pulmonary alveolar microlithiasis. Hum Genome Var. 2017;4:16047.
27.\Dogan OT, Ozsahin SL, Gul E, et al. A frame-shift mutation in the SLC34A2 gene in three patients with pulmonary alveolar microlithiasis in an inbred family. Intern Med. 2010;49(1):45–9.
28.\Ishihara Y, Hagiwara K, Zen K, Huqun, Hosokawa Y, Natsuhara A. A case of pulmonary alveolar microlithiasis with an intragenetic deletion in SLC34A2 detected by a genome-wide SNP study. Thorax. 2009;64(4):365–67.
29.\Ozcelik U, et al. Long-term results of disodium etidronate treatment in pulmonary alveolar microlithiasis. Pediatr Pulmonol. 2010;45(5):514–7.
30.\Ozbudak IH, Bassorgun CI, Ozbilim G, et al. Pulmonary alveolar microlithiasis with homozygous c.316G > C (p.G106R) mutation: a case report. Turk Patoloji Derg. 2012;28(3):282–5.
31.\Dandan S, et al. Novel deletion of SLC34A2 in Chinese patients of PAM shares mutation hot spot with fusion gene SLC34A2-ROS1 in lung cancer. J Genet. 2018;97(4):939–44. PMID: 30262706.
32.\Ma T, et al. A pedigree with pulmonary alveolar microlithiasis: a clinical case report and literature review. Cell Biochem Biophys. 2014;70(1):565–72.
33.\Zhong YQ, Hu CP, Cai XD, Nie HP. [A novel mutation of the SLC34A2 gene in a Chinese pedigree with pulmonary alveolar microlithiasis]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2009;26(4):365–68.
34.\Yin X, Wang H, Wu D, Zhao G, Shao J, Dai Y. SLC34A2 Gene mutation of pulmonary alveolar microlithiasis: report of four cases and review of literatures. Respir Med. 2013;107(2):217–22.
35.\Wang H, Yin X, Wu D, Jiang X. SLC34A2 gene compound heterozygous mutation identi cation in a patient with pulmonary alveolar
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
27 Pulmonary Alveolar Microlithiasis |
485 |
|
|
microlithiasis and computational 3D protein structure prediction. Meta Gene. 2014;2:557–64.
36.\Proesmans M, et al. Pulmonary alveolar microlithiasis: a case report and review of the literature. Eur J Pediatr. 2012;171(7):1069–72. https://doi.org/10.1007/s00431-012-1678-8. Epub 4 Feb 2012. PMID: 22311166.
37.\Yang W, et al. Elevated expression of SLC34A2 inhibits the viability and invasion of A549 cells. Mol Med Rep. 2014;10(3):1205–14.
38.\Traebert M, et al. Expression of type II Na-P(i) cotransporter in alveolar type II cells. Am J Phys. 1999;277(5):L868–73.
39.\Hashimoto M, et al. Isolation and localization of type IIb Na/ Pi cotransporter in the developing rat lung. Am J Pathol. 2000;157(1):21–7.
40.\Sabbagh Y, et al. Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol. 2009;20(11):2348–58.
41.\Schiavi SC, et al. Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol. 2012;23(10):1691–700.
42.\Saito A, et al. Modeling pulmonary alveolar microlithiasis by epithelial deletion of the Npt2b sodium phosphate cotransporter reveals putative biomarkers and strategies for treatment. Sci Transl Med. 2015;7(313):313ra181.
43.\Takahashi H, et al. Elevated serum surfactant protein a and D in pulmonary alveolar microlithiasis. Respirology. 2006;11(3):330–3.
44.\Monabati A, Ghayumi MA, Kumar PV. Familial pulmonary alveolar microlithiasis diagnosed by bronchoalveolar lavage. A case report. Acta Cytol. 2007;51(1):80–2.
45.\Caffrey PR, Altman RS. Pulmonary alveolar microlitbiasis occurring in premature twins. J Pediatr. 1965;66:758–63.
46.\Mariotta S, et al. Pulmonary alveolar microlithiasis: report on 576 cases published in the literature. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21(3):173–81.
47.\Meyer HH, Gilbert ES, Kent G. A clinical review of pulmonary microlithiasis. J Am Med Assoc. 1956;161(12):1153–7.
48.\Coetzee T. Pulmonary alveolar microlithiasis with involvement of the sympathetic nervous system and gonads. Thorax. 1970;25(5):637–42.
49.\Sandhyamani S, et al. Pulmonary alveolar microlithiasis. Indian J Chest Dis Allied Sci. 1982;24(1):33–5.
50.\Arslan A, et al. Pulmonary alveolar microlithiasis associated with calci cations in the seminal vesicles. J Belg Radiol. 1996;79(3):118–9.
51.\Kanat F, Teke T, Imecik O. Pulmonary alveolar microlithiasis with epididymal and periurethral calci cations causing obstructive azospermia. Int J Tuberc Lung Dis. 2004;8(10):1275.
52.\Qublan HS, Athamneh I, Al-Kaisi NS. Azoospermia associated with testicular and pulmonary microlithiasis. J Diagn Med Sonograp. 2003;19(3):192–4.
53.\Sumikawa H, et al. Pulmonary alveolar microlithiasis: CT and pathologic ndings in 10 patients. Monaldi Arch Chest Dis. 2005;63(1):59–64.
54.\Kim B, Winter TC 3rd, Ryu JA. Testicular microlithiasis: clinical signi cance and review of the literature. Eur Radiol. 2003;13(12):2567–76.
55.\Middleton WD, Teefey SA, Santillan CS. Testicular microlithiasis: prospective analysis of prevalence and associated tumor. Radiology. 2002;224(2):425–8.
56.\Miller FN, Sidhu PS. Does testicular microlithiasis matter? A review. Clin Radiol. 2002;57(10):883–90.
57.\Prakash UB, et al. Pulmonary alveolar microlithiasis. A review including ultrastructural and pulmonary function studies. Mayo Clin Proc. 1983;58(5):290–300.
58.\Tachibana T, Hagiwara K, Johkoh T. Pulmonary alveolar microlithiasis: review and management. Curr Opin Pulm Med. 2009;15(5):486–90.
59.\Balikian JP, Fuleihan FJ, Nucho CN. Pulmonary alveolar microlithiasis. Report of ve cases with special reference to roentgen manifestations. Am J Roentgenol Radium Therapy, Nucl Med. 1968;103(3):509–18.
60.\Cluzel P, et al. Pulmonary alveolar microlithiasis: CT ndings. J Comput Assist Tomogr. 1991;15(6):938–42.
61.\Deniz O, et al. High resolution computed tomographic features of pulmonary alveolar microlithiasis. Eur J Radiol. 2005;55(3):452–60.
62.\Marchiori E, et al. Pulmonary alveolar microlithiasis: high- resolution computed tomography ndings in 10 patients. J Bras Pneumol. 2007;33(5):552–7.
63.\Francisco FA, et al. Can chest high-resolution computed tomography ndings diagnose pulmonary alveolar microlithiasis? Radiol Bras. 2015;48(4):205–10.
64.\Gasparetto EL, et al. Pulmonary alveolar microlithiasis presenting with crazy-paving pattern on high resolution CT. Br J Radiol. 2004;77(923):974–6.
65.\Belem LC, et al. Metastatic pulmonary calci cation: state- of-the-art review focused on imaging ndings. Respir Med. 2014;108(5):668–76.
66.\Chatterji R, Gaude GS, Patil PV. Pulmonary alveolar microlithiasis: diagnosed by sputum examination and transbronchial biopsy. Indian J Chest Dis Allied Sci. 1997;39(4):263–7.
67.\Martinez-Giron R, Martinez-Torre S. Calci ed Curschmann’s spirals and microliths in sputum smears from a case of pulmonary alveolar microlithiasis. Diagn Cytopathol. 2017;45(12):1116–8.
68.\Arpag H, et al. A case of pulmonary alveolar microlithiasis diagnosed by transbronchial biopsy. Turk Thorac J. 2017;18(4):134–6.
69.\Castellana G, et al. Pulmonary alveolar microlithiasis: clinical features, evolution of the phenotype, and review of the literature. Am J Med Genet. 2002;111(2):220–4.
70.\Watts NB, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990;323(2):73–9.
71.\Allgrove J. Biphosphonates. Arch Dis Child. 1997;76(1):73–5. 72.\Mariotta S, et al. Pulmonary microlithiasis. Report of two cases.
Respiration. 1997;64(2):165–9.
73.\Kumazoe H, et al. “Reversed halo sign” of high-resolution computed tomography in pulmonary sarcoidosis. J Thorac Imaging. 2009;24(1):66–8.
74.\Ozcelik U, et al. Treatment and follow-up of pulmonary alveolar microlithiasis with disodium editronate: radiological demonstration. Pediatr Radiol. 2002;32(5):380–3.
75.\Jankovic S, et al. Pulmonary alveolar microlithiasis in childhood: clinical and radiological follow-up. Pediatr Pulmonol. 2002;34(5):384–7.
76.\Cakir E, et al. Response to disodium etidronate treatment in three siblings with pulmonary alveolar microlithiasis. Respiration. 2015;89(6):583–6.
77.\Emiralioglu N, et al. Diagnosis and treatment of pulmonary alveolar microlithiasis. Pediatr Int. 2016;58(8):805–7.
78.\Taille C, et al. Calcium-solubilizing sodium thiosulfate failed to improve pulmonary alveolar microlithiasis: evaluation of calcium content with CT scan. Respir Med Res. 2019;75:10–2.
79.\Palombini BC, et al. Bronchopulmonary lavage in alveolar microlithiasis. Chest. 1981;80(2):242–3.
80.\Palombini BC, et al. Bronchopulmonary lavage in alveolar microlithiasis. Anaesth Intensive Care. 1978;6(3):265.
81.\Mascie-Taylor BH, et al. A case of alveolar microlithiasis: observation over 22 years and recovery of material by lavage. Thorax. 1985;40(12):952–3.
486 |
C. D. Lampl et al. |
|
|
82.\Devine OP, Harborne AC. Pneumothorax secondary to pulmonary alveolar microlithiasis. Clin Case Rep. 2018;6(4):764–5.
83.\Jackson KB, et al. Single lung transplantation for pulmonary alveolar microlithiasis. J Heart Lung Transplant. 2001;20(2):226.
84.\Stamatis G, et al. Sequential bilateral lung transplantation for pulmonary alveolar microlithiasis. Ann Thorac Surg. 1993;56(4):972–5.
85.\Borrelli R, et al. Right single-lung transplantation for pulmonary alveolar microlithiasis. Eur J Cardiothorac Surg. 2014;45(2):e40.
86.\Bonnette P, et al. Bilateral single lung transplantation. Complications and results in 14 patients. Eur J Cardiothorac Surg. 1992;6(10):550–4.
87.\Edelman JD, et al. Bilateral sequential lung transplantation for pulmonary alveolar microlithiasis. Chest. 1997;112(4):1140–4.
88.\Alrossais NM, et al. Pulmonary hypertension and polycythemia secondary to pulmonary alveolar microlithiasis treated with sequential bilateral lung transplant: a case study and literature review. Am J Case Rep. 2019;20:1114–9.
89.\Jindal A, et al. Pulmonary alveolar microlithiasis: a rare disease treated with lung transplantation, rst case from India. Lung India. 2019;36(6):546–9.
90.\Shigemura N, et al. Lung transplantation for pulmonary alveolar microlithiasis. J Thorac Cardiovasc Surg. 2010;139(3):e50–2.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/